JAZZ Annual Accounts Receivable
$705.79 M
+$54.30 M+8.33%
31 December 2023
Summary:
As of January 22, 2025, JAZZ annual accounts receivable is $705.79 million, with the most recent change of +$54.30 million (+8.33%) on December 31, 2023. During the last 3 years, it has risen by +$309.30 million (+78.01%). JAZZ annual accounts receivable is now at all-time high.JAZZ Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Quarterly Accounts Receivable
$723.64 M
+$25.60 M+3.67%
30 September 2024
Summary:
As of January 22, 2025, JAZZ quarterly accounts receivable is $723.64 million, with the most recent change of +$25.60 million (+3.67%) on September 30, 2024. Over the past year, it has increased by +$95.80 million (+15.26%). JAZZ quarterly accounts receivable is now at all-time high.JAZZ Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
JAZZ Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +8.3% | +15.3% |
| 3 y3 years | +78.0% | +15.3% |
| 5 y5 years | +167.5% | +15.3% |
JAZZ Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +25.3% | at high | +28.4% |
| 5 y | 5-year | at high | +98.3% | at high | +128.1% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
Jazz Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $723.64 M(+3.7%) |
| June 2024 | - | $698.04 M(-1.3%) |
| Mar 2024 | - | $707.10 M(+0.2%) |
| Dec 2023 | $705.79 M(+8.3%) | $705.79 M(+12.4%) |
| Sept 2023 | - | $627.84 M(+2.9%) |
| June 2023 | - | $610.39 M(-2.2%) |
| Mar 2023 | - | $623.94 M(-4.2%) |
| Dec 2022 | $651.49 M(+15.6%) | $651.49 M(+8.4%) |
| Sept 2022 | - | $601.18 M(+1.2%) |
| June 2022 | - | $594.03 M(+3.8%) |
| Mar 2022 | - | $572.39 M(+1.6%) |
| Dec 2021 | $563.36 M(+42.1%) | $563.36 M(+12.9%) |
| Sept 2021 | - | $499.02 M(-1.5%) |
| June 2021 | - | $506.66 M(+22.4%) |
| Mar 2021 | - | $413.98 M(+4.4%) |
| Dec 2020 | $396.49 M(+11.4%) | $396.49 M(+9.6%) |
| Sept 2020 | - | $361.66 M(+2.8%) |
| June 2020 | - | $351.92 M(+10.9%) |
| Mar 2020 | - | $317.30 M(-10.9%) |
| Dec 2019 | $355.99 M(+34.9%) | $355.99 M(+33.3%) |
| Sept 2019 | - | $267.03 M(-14.2%) |
| June 2019 | - | $311.25 M(-2.9%) |
| Mar 2019 | - | $320.49 M(+21.5%) |
| Dec 2018 | $263.84 M(+17.7%) | $263.84 M(-5.6%) |
| Sept 2018 | - | $279.44 M(+0.4%) |
| June 2018 | - | $278.44 M(-1.1%) |
| Mar 2018 | - | $281.42 M(+25.6%) |
| Dec 2017 | $224.13 M(-4.3%) | $224.13 M(-13.3%) |
| Sept 2017 | - | $258.62 M(+8.3%) |
| June 2017 | - | $238.75 M(-1.8%) |
| Mar 2017 | - | $243.03 M(+3.8%) |
| Dec 2016 | $234.24 M(+11.7%) | $234.24 M(-1.6%) |
| Sept 2016 | - | $238.07 M(+2.7%) |
| June 2016 | - | $231.84 M(+3.6%) |
| Mar 2016 | - | $223.80 M(+6.7%) |
| Dec 2015 | $209.69 M | $209.69 M(+7.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2015 | - | $195.82 M(+1.1%) |
| June 2015 | - | $193.65 M(+2.1%) |
| Mar 2015 | - | $189.68 M(+1.8%) |
| Dec 2014 | $186.37 M(+49.3%) | $186.37 M(-0.7%) |
| Sept 2014 | - | $187.60 M(+16.7%) |
| June 2014 | - | $160.78 M(+3.7%) |
| Mar 2014 | - | $154.99 M(+24.2%) |
| Dec 2013 | $124.81 M(+65.3%) | $124.81 M(+10.2%) |
| Sept 2013 | - | $113.27 M(-0.7%) |
| June 2013 | - | $114.08 M(+21.6%) |
| Mar 2013 | - | $93.83 M(+24.3%) |
| Dec 2012 | $75.48 M(+119.6%) | $75.48 M(-14.5%) |
| Sept 2012 | - | $88.30 M(+13.0%) |
| June 2012 | - | $78.13 M(+39.2%) |
| Mar 2012 | - | $56.14 M(+63.3%) |
| Dec 2011 | $34.37 M(+55.7%) | $34.37 M(+9.4%) |
| Sept 2011 | - | $31.43 M(+25.7%) |
| June 2011 | - | $25.00 M(+16.9%) |
| Mar 2011 | - | $21.38 M(-3.2%) |
| Dec 2010 | $22.08 M(+79.3%) | $22.08 M(+56.7%) |
| June 2010 | - | $14.10 M(+17.9%) |
| Mar 2010 | - | $11.96 M(-2.9%) |
| Dec 2009 | $12.31 M(+85.4%) | $12.31 M(+33.8%) |
| Sept 2009 | - | $9.20 M(+0.1%) |
| June 2009 | - | $9.20 M(+31.2%) |
| Mar 2009 | - | $7.01 M(+5.6%) |
| Dec 2008 | $6.64 M(+23.3%) | $6.64 M(-0.6%) |
| Sept 2008 | - | $6.69 M(+28.1%) |
| June 2008 | - | $5.22 M(-1.7%) |
| Mar 2008 | - | $5.31 M(-1.5%) |
| Dec 2007 | $5.39 M(+0.2%) | $5.39 M(-17.9%) |
| Sept 2007 | - | $6.57 M(+1.6%) |
| June 2007 | - | $6.46 M(+4.8%) |
| Mar 2007 | - | $6.17 M(+14.6%) |
| Dec 2006 | $5.38 M(+49.6%) | $5.38 M(+49.6%) |
| Dec 2005 | $3.60 M | $3.60 M |
FAQ
- What is Jazz Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals annual accounts receivable year-on-year change?
- What is Jazz Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Jazz Pharmaceuticals?
- What is Jazz Pharmaceuticals quarterly accounts receivable year-on-year change?
What is Jazz Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of JAZZ is $705.79 M
What is the all time high annual accounts receivable for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high annual accounts receivable is $705.79 M
What is Jazz Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, JAZZ annual accounts receivable has changed by +$54.30 M (+8.33%)
What is Jazz Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of JAZZ is $723.64 M
What is the all time high quarterly accounts receivable for Jazz Pharmaceuticals?
Jazz Pharmaceuticals all-time high quarterly accounts receivable is $723.64 M
What is Jazz Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, JAZZ quarterly accounts receivable has changed by +$95.80 M (+15.26%)